BioLine RX Ltd (BLRX)

Currency in ILS
2.5
0.0(0.00%)
Closed·
BLRX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
BLRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.42.5
52 wk Range
1.419.9
Key Statistics
Bid/Ask
2.40 / 2.50
Prev. Close
2.5
Open
2.5
Day's Range
2.4-2.5
52 wk Range
1.4-19.9
Volume
241.2K
Average Volume (3m)
9.66M
1-Year Change
-86.91%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BLRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

BioLine RX Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Strong Sell

BioLine RX Ltd Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Compare BLRX to Peers and Sector

Metrics to compare
BLRX
Peers
Sector
Relationship
P/E Ratio
−5.6x−2.0x−0.5x
PEG Ratio
−0.06−0.030.00
Price/Book
0.9x2.6x2.6x
Price / LTM Sales
0.9x9.3x3.2x
Upside (Analyst Target)
-433.3%41.6%
Fair Value Upside
Unlock18.3%6.0%Unlock

Earnings

Latest Release
May 27, 2025
EPS / Forecast
-- / -0.002
Revenue / Forecast
255.00K / 792.00K
EPS Revisions
Last 90 days

BLRX Income Statement

People Also Watch

5,595
TEVA
-0.78%
39.22
BMNR
-1.46%
16,830
CLIS
-3.28%
69,200
DLEKG
-0.76%
8,665
MTAV
+1.03%

FAQ

What Stock Exchange Does Bioline Rx Trade On?

Bioline Rx is listed and trades on the Tel Aviv Stock Exchange stock exchange.

What Is the Stock Symbol for Bioline Rx?

The stock symbol for Bioline Rx is "BLRX."

What Is the Bioline Rx Market Cap?

As of today, Bioline Rx market cap is 61.38M.

What Is Bioline Rx's Earnings Per Share (TTM)?

The Bioline Rx EPS (TTM) is -0.00.

When Is the Next Bioline Rx Earnings Date?

Bioline Rx will release its next earnings report on 12 Aug 2025.

From a Technical Analysis Perspective, Is BLRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Bioline Rx Stock Split?

Bioline Rx has split 1 times.

How Many Employees Does Bioline Rx Have?

Bioline Rx has 28 employees.

What is the current trading status of Bioline Rx (BLRX)?

As of 28 Jul 2025, Bioline Rx (BLRX) is trading at a price of 2.50, with a previous close of 2.50. The stock has fluctuated within a day range of 2.40 to 2.50, while its 52-week range spans from 1.40 to 19.90.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.